Approval for the x stoppk, a modified version of the x stop that includes a peek spacer and additional 16 mm spacer size.  The device, as modified, will be marketed under the trade name x stoppk and is indicated for treatment of patients aged 50 or older suffering from neurogenic intermittent claudication secondary to a confirmed diagnosis of lumbar spinal stenosis (with x-ray, mri, and/or ct evidence of thickening ligamentum flavum, narrowed lateral recess and/or central conal narrowing).  The x stoppk is indicated  for those patients with moderately impaired physical function who experience relief in flexion from their symptoms of leg/buttock/groin pain, with or without back pain, and have undergone a regimen of at least 6 months of nonoperative treatment.  The x stoppk may be implanted at one or two lumbar levels in patients in whom operative treatment is indicated at no more than two levels.